Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,465 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Control Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Kent State University / Price Chopper Employee Wellness Study

NCT03454009
View directory record Official record
Conditions
Acute Respiratory Infection, Influenza-like Illness, Gastrointestinal Infection
Interventions
Multimodal hygiene intervention
Behavioral
Lead sponsor
Kent State University
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Schenectady, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Not applicable Interventional

Music Therapy During Pediatric Extubation Readiness Trials

NCT02845947
View directory record Official record
Conditions
Respiratory Insufficiency
Interventions
Music Therapy
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
Up to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 23, 2026, 6:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

NCT05877508
View directory record Official record
Conditions
Long COVID, Post-Acute Sequela of COVID-19, Post-Acute COVID-19
Interventions
AER002, Placebo
Drug · Other
Lead sponsor
Michael Peluso, MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 23, 2026, 6:42 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

pH1N1 Blinded Challenge Study

NCT07110532
View directory record Official record
Conditions
Influenza
Interventions
A/Arkansas/08/2020 (pH1N1), Sham/Diluent (1X SPG+Arg+Gel)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 3 Interventional

A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia

NCT00001104
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
23
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis

NCT01482052
View directory record Official record
Conditions
Meningococcal Meningitis, Meningococcal Infections
Interventions
meningococcal meningitis conjugate vaccine, quadrivalent
Biological
Lead sponsor
JN-International Medical Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hanford, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

NCT02563106
View directory record Official record
Conditions
Clostridium Difficile, Clostridium Infections
Interventions
SYN-004, Placebo
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Little Rock, Arkansas • Torrance, California • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients

NCT00002446
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Posaconazole, Fluconazole
Drug
Lead sponsor
Schering-Plough
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
17
States / cities
Berkeley, California • San Francisco, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Trial Comparing the Optimal Timing of Antibiotic Prophylaxis at the Time of Cesarean Delivery

NCT00811603
View directory record Official record
Conditions
Cesarean Section, Infection
Interventions
Cefazolin (Timing of Antibiotic Prophylaxis)
Drug
Lead sponsor
MemorialCare
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Long Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2009 · Synced Oct 23, 2026, 6:42 AM EDT
Terminated Not applicable Interventional

Computer-Assisted Treatment of Urinary Tract Infection in Emergency Departments and Community Health Centers

NCT00731315
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Computer-assisted treatment group, Usual care group
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Fresno, California • Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Not applicable Interventional

Supplemental Perioperative Oxygen to Reduce Surgical Site Infection After High Energy Fracture Surgery

NCT01798810
View directory record Official record
Conditions
Post Operative Surgical Site Infection
Interventions
Supplemental Perioperative Oxygen
Procedure
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
1,171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Phoenix, Arizona • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

NCT04603924
View directory record Official record
Conditions
COVID-19
Interventions
Niclosamide, Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Sheffield, Alabama • Irvine, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients

NCT00001082
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Levocarnitine, Adefovir dipivoxil, Adefovir dipivoxil placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 23, 2026, 6:42 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement

NCT06577220
View directory record Official record
Conditions
Cervical Cancer, Human Papillomavirus Infection
Interventions
Telephone Recall, Mailed HPV Self-Sampling Kit, Patient Navigation
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 2 Interventional

Topical PluroGel N for the Treatment of Mildly Infected Diabetic Foot Ulcers

NCT02091596
View directory record Official record
Conditions
Diabetic Foot Ulcer, Infection
Interventions
PluroGel N, PluroGel
Drug
Lead sponsor
PluroGen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 23, 2026, 6:42 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

NCT04401527
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
Interventions
Sodium Nitrite, Normal Saline
Drug
Lead sponsor
Hope Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Tampa, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 4 Interventional

Animal-Assisted Visitation Program Chlorhexidine Trial

NCT04171817
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile, Pseudomonas Aeruginosa
Interventions
Chlorhexidine
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
3 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
9vHPV Vaccine, Placebo (Saline for Injection)
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
6,033 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
32
States / cities
Northridge, California • Rialto, California • Simi Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection

NCT04233424
View directory record Official record
Conditions
Surgical Site Infection, Colon Surgery, Abdominal Surgery, Post-Op Infection
Interventions
D-PLEX, Standard of Care (SoC)
Drug
Lead sponsor
PolyPid Ltd.
Industry
Eligibility
18 Years to 99 Years
Enrollment
977 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Sheffield, Alabama • Los Angeles, California • Redding, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

NCT03979313
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MEDI8897, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 1 Year
Enrollment
3,012 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
66
States / cities
Birmingham, Alabama • Fort Defiance, Arizona • Fayetteville, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 23, 2026, 6:42 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

NCT05305040
View directory record Official record
Conditions
Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
Interventions
Posoleucel (ALVR105), Placebo
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

NCT02367313
View directory record Official record
Conditions
Asthma
Interventions
Vapendavir, Placebo
Drug
Lead sponsor
Biota Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Bakersfield, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 23, 2026, 6:42 AM EDT
Not listed No phase listed Observational

The DETECT(Digital Engagement & Tracking for Early Control, & Treatment) Study

NCT04336020
View directory record Official record
Conditions
Influenza, Virus
Interventions
Not listed
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants

NCT00407082
View directory record Official record
Conditions
Noninfectious Posterior Uveitis
Interventions
fluocinolone acetonide intravitreal implant, Fluocinolone acetonide 2.1mg
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
6 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Oct 23, 2026, 6:42 AM EDT